Small molecule · Inhibitor of EGFR · developed by Alpha Biopharma Co.
Zorifertinib is an orally available inhibitor of EGFR and certain mutant forms of EGFR. It prevents EGFR-mediated signaling, leading to induction of cell death and inhibition of tumor growth in EGFR-overexpressing cells. It is studied in EGFR-mutant advanced non-small cell lung cancer, including cases with CNS metastases and leptomeningeal progression.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03653546 | Phase 2/3 | Non-small Cell Lung Cancer | Completed | ACOG |
| NCT07551414 | Phase 2 | NSCLC (Non-small Cell Lung Carcinoma) | Not yet recruiting | ACOG |
| NCT07620951 | Phase 1 | EGFR Mutant Advanced Non-small Cell Lung Cancer | Completed | ACOG |
| NCT07361705 | Phase 1 | Patients With Advanced Non-small Cell Lung Cancer With Meningeal Progression… | Recruiting | ACOG |
| NCT07143045 | N/A | EGFR Mutant Advanced Non-small Cell Lung Cancer | Recruiting | ACOG |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Central Nervous System (CNS) MetastasesEGFR Mutant Advanced Non-small Cell Lung CancerEGFR-TKI Sensitizing MutationLeptomeningeal MetastasisNSCLC (Non-small Cell Lung Carcinoma)ZorifertinibBrain MetastasesEGFR Gene MutationNon-small Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the ACOG page.
See ACOG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ACOG catalysts and pipeline →